Vaxcyte (PCVX) announced that it has commenced an underwritten public offering of $500M of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. BofA Securities, Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte provides update on development of VAX-31 pneumococcal vaccine
- Needham ups Vaxcyte target, adds to Conviction List
- Buy Rating on Vaxcyte: De-Risked VAX-31 Clinical Profile, Strong Cash Position, and Attractive Entry Ahead of 2026 Phase 3 Catalyst
- Mizuho positive on Vaxcyte after HHS maintains PCV schedule for children
- Vaxcyte Enhances Executive Severance to Align With Market